Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Dalal, Anand A ^a   Shah, Manan B ^b   D'Souza, Anna O ^b   Lunacsek, Orsolya E ^b   Nagar, Saurabh P ^a   Crater, Glenn D ^a  

^a GLAXOSMITHKLINE   (United States)

^b XCENDA   (United States)

Author keywords

Anticholinergics; Chronic obstructive pulmonary disease; Costs; Fluticasone propionate salmeterol combination; Moderate COPD exacerbations

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; ADRENERGIC RECEPTOR STIMULATING AGENT; ANDROSTANE DERIVATIVE; DRUG DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DISEASE EXACERBATION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOME OXYGEN THERAPY; HOSPITALIZATION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; ECONOMICS; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; UNITED STATES;

ALBUTEROL; ANDROSTADIENES; CHOLINERGIC ANTAGONISTS; DRUG COMBINATIONS; FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYMPATHOMIMETICS; TREATMENT OUTCOME; UNITED STATES;

EID: 84861630457     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-41     Document Type: Article

References (17)

1. GOLD Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Updated 2010. Available from: www.goldcopd.com. Accessed March 1, 2011, GOLD Global Initiative for Chronic Obstructive Lung Disease.
2. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung HC. Deaths: Preliminary Data for 2009. Natl Vital Stat Rep 2001, 59(4):1-69.
3. NHLBI Morbidity and Mortality Chart Book National Heart 2009, Bethesda: Lung and Blood Institute, NHLBI Morbidity and Mortality Chart Book.
4. Jansson SA, Andersson F, Borg S, Ericsson A, Jönsson E, Lundbäck B. Costs of COPD in Sweden according to disease severity. Chest 2002, 122(6):1994-2002. 10.1378/chest.122.6.1994, 12475838.
5. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011, 14(3):315-323. 10.3111/13696998.2011.576295, 21500975.
6. Minas M, Hatzoglou C, Karetsi E, Papaioannou AI, Tanou K, Tsaroucha R, Gogou E, Gourgoulianis KI, Kostikas K. COPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry program. Prim Care Resp J 2010, 19(4):363-370.
7. Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R. Newly diagnosed chronic obstructive pulmonary disease. Respiration 2003, 70:67-75. 10.1159/000068417, 12584394.
8. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. CMRO 2011, 27(7):1425-1429.
9. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59. 10.1186/1465-9921-10-59, 2714501, 19566934.
10. Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006, 129(6):1509-1515. 10.1378/chest.129.6.1509, 16778268.
11. Lee TA, Schumock GT, Bartle B, Pickard AS. Mortality risk in chronic obstructive pulmonary disease patients using theophylline. Effective Health Care Research Report No. 16. (Prepared by Chicago-Area DEcIDE Center Under Contract No. HHSA29020050038I TO1) 2009, Rockville: Agency for Healthcare Research and Quality, http://effectivehealthcare.ahrq.gov/reports/final.cfm.
12. Diette GB, Orr P, McCormack MC, Gandy W, Hamar B. Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines?. Popul Health Manag 2010, 12(1):21-26.
13. Feifer RA, Aubert R, Verbrugge RR, Khalid M. Disease management opportunities for chronic obstructive pulmonary disease: Gaps between guidelines and current practice. Dis Manag 2002, 5:143-156.
14. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008, 134(2):255-262.
15. Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone. Respirology 2009, 14(2):239-244. 10.1111/j.1440-1843.2008.01452.x, 19210650.
16. Bateman ED, van Dyk M, Sagriotis A. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulm Pharmacol Ther 2008, 21(1):20-25. 10.1016/j.pupt.2006.10.001, 17118684.
17. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, . UPLIFT investigators Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009, 374(9696):1171-1178. 10.1016/S0140-6736(09)61298-8, 19716598, UPLIFT investigators.